Document Detail


Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
MedLine Citation:
PMID:  10689266     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: A preliminary study suggested that the long-acting late-generation calcium-channel blocker amlodipine has favorable effects on exercise tolerance and is safe to use in heart failure, in contrast to earlier generation agents. The goal of 2 multicenter studies was to assess the effect of adjunctive therapy with amlodipine in addition to standard therapy on exercise capacity, quality of life, left ventricular function, and safety parameters in patients with heart failure and left ventricular systolic dysfunction. METHODS: Two large multicenter trials examining the effects of amlodipine on these parameters over a 12-week period of therapy were undertaken in patients with mild to moderate heart failure and left ventricular systolic dysfunction. A total of 437 patients with stable heart failure were studied in a randomized, double-blind, placebo-controlled prospective design. RESULTS: Amlodipine at a dose of 10 mg/day in addition to standard therapy in such patients was associated with no significant difference in change in exercise tolerance on a Naughton protocol compared with placebo in each trial. Among all patients taking amlodipine, exercise time increased 53 +/- 9 (SE) seconds; exercise time for those taking placebo increased 66 +/- 9 seconds (P = not significant). There were no significant differences in changes of quality of life parameters between amlodipine- and placebo-treated patients, and there were no significant differences in symptom scores or New York Heart Association classification between groups. Left ventricular function (measured as ejection fraction) improved 3. 4% +/- 0.5% in amlodipine-treated patients and 1.5% +/- 0.5% in placebo-treated patients (P =.007). There was no statistically significant excess of important adverse events (episodes of worsening heart failure in 10% amlodipine-treated vs 6.3% of placebo-treated patients) or differences in need for changes in background medication between groups. CONCLUSIONS: The addition of 10 mg of amlodipine per day to standard therapy in patients with heart failure is associated with no significant improvement in exercise time compared with placebo therapy over a 12-week period, and there was no increased incidence of adverse events. These data suggest that the addition of amlodipine to standard therapy in heart failure will not result in additional efficacy per se beyond standard therapy.
Authors:
J E Udelson; C A DeAbate; M Berk; G Neuberg; M Packer; N K Vijay; J Gorwitt; W B Smith; M L Kukin; T LeJemtel; T B Levine; M A Konstam
Related Documents :
2841136 - A randomized cross-over study of enalapril in congestive heart failure: haemodynamic an...
12558126 - Comparison of cardiovascular responses to isometric (static) and isotonic (dynamic) exe...
7214396 - A differential inotropic responsiveness to isoprenaline and ouabain in dogs with heart ...
2262216 - Sustained beneficial effects of enalapril in africans with congestive heart failure.
24450966 - Exercise-induced skeletal muscle remodeling and metabolic adaptation: redox signaling a...
9247996 - Aging, work, life-style and work ability among finnish municipal workers in 1981-1992.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American heart journal     Volume:  139     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-04-07     Completed Date:  2000-04-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  503-10     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology, Department of Medicine, New England Medical Center, Boston, MA 02111, USA. james.udelson@es.nemc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Amlodipine / adverse effects,  therapeutic use*
Calcium Channel Blockers / adverse effects,  therapeutic use*
Double-Blind Method
Exercise Test
Exercise Tolerance / drug effects*
Female
Heart Failure / drug therapy*,  etiology
Hemodynamics / drug effects
Humans
Male
Middle Aged
Quality of Life*
Severity of Illness Index
Treatment Outcome
Ventricular Dysfunction, Left / complications,  drug therapy*
Ventricular Function, Left / drug effects
Walking
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of left ventricular regional relaxation abnormalities and asynchrony in patients with hype...
Next Document:  A rationale for the use of beta-blockers as standard treatment for heart failure.